
To demonstrate the efficacy and cost‐effectiveness of acute ESWL for ureteric stones the study present our experience of ESWL in 530 ureteric stone cases, in the largest UK series we are aware of to date. ESWL is underutilised in ureteric stone management. The GIRFT report showed just four units nationally treated >10% of acute ureteric stones with ESWL. Despite guideline recommendations as a first‐line treatment option, few large volume studies have been published. Acute ESWL is a safe, reliable, and financially viable treatment option for a wider spectrum of patients than reflected in international guidelines based on our large, heterogenous series. In the COVID‐19 era, with theatre access reduced and concerns over aerosol generating procedures, acute ESWL remains an attractive first‐line treatment option.
Like
Save
Share